key: cord-0940367-rw37biop authors: Shannon, Ashleigh; Tuyet Le, Nhung Thi; Selisko, Barbara; Eydoux, Cecilia; Alvarez, Karine; Guillemot, Jean-Claude; Decroly, Etienne; Peersen, Olve; Ferron, Francois; Canard, Bruno title: Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites date: 2020-04-10 journal: Antiviral Res DOI: 10.1016/j.antiviral.2020.104793 sha: 1e8874fb92f6e4e828b2b4e7521396f1b1132a6c doc_id: 940367 cord_uid: rw37biop The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target of choice for the prophylactic or curative treatment of several viral diseases, due to high sequence and structural conservation. To date, the most promising broad-spectrum class of viral RdRp inhibitors are nucleoside analogues (NAs), with over 25 approved for the treatment of several medically important viral diseases. However, Coronaviruses stand out as a particularly challenging case for NA drug design due to the presence of an exonuclease (ExoN) domain capable of excising incorporated NAs and thus providing resistance to many of these available antivirals. Here we use the available structures of the SARS-CoV RdRp and ExoN proteins, as well as Lassa virus N exonuclease to derive models of catalytically competent SARS-CoV-2 enzymes. We then map a promising NA candidate, GS-441524 (the active metabolite of Remdesivir) to the nucleoside active site of both proteins, identifying the residues important for nucleotide recognition, discrimination, and excision. Interestingly, GS-441524 addresses both enzyme active sites in a manner consistent with significant incorporation, delayed chain termination, and altered excision due to the ribose 1'-CN group, which may account for the increased antiviral effect compared to other available analogues. Additionally, we propose structural and function implications of two previously identified RdRp resistance mutations in relation to resistance against Remdesivir. This study highlights the importance of considering the balance between incorporation and excision properties of NAs between the RdRp and ExoN. The recent emergence of a new SARS-like coronavirus in December 2019 (now named SARS-CoV-2) likely from the Huanan seafood market in Wuhan China, is the cause of significant global health concern. SARS-CoV-2 has been shown to be closest related (~88%) to two bat-derived SARS-like CoVs (bat-SL-CoVZC45 and bat-SL-CoVZXC21), with ~79% overall sequence identity to SARS-CoV and ~50% to MERS-CoV. At the present time, any mention of the number of cases, affected countries, and case/fatality ratio will be outdated at print time. Coronaviruses (CoV) are enveloped, positive-sense RNA viruses of the order Nidovirales, with genome sizes ranging from 26 to 32 kilobases 1 Potential broad-spectrum targets include viral gene products that are widely conserved and do not exist in the host cell, or that are structurally and functionally different enough from cellular homologous to achieve selective inhibition. For RNA viruses, the RNA-dependent RNA polymerase (RdRp) presents an optimal target due to its crucial role in RNA synthesis, lack of host homolog and high sequence and structural conservation. The RdRp remains the target of choice for the treatment of several viral diseases, including chronic liver disease caused by hepatitis C virus infection. Arguably the most promising, broad-spectrum class of viral RdRp inhibitors are nucleos(t)ide analogues (NAs). Upon delivery into the host cell, nucleoside/nucleotide prodrugs are metabolized into an active 5'triphosphate form (5'-TP) which competes with endogenous nucleotides as substrates for the viral RdRp. The NAs are subsequently incorporated into the nascent viral RNA by the RdRp, accounting for the antiviral effect through several mechanisms of action (MoA). Firstly, NA incorporation may cause termination of RNA synthesis. This can be either obligate, i.e. the analogue lacks a 3'-OH required for RNA chain extension, or non-obligate, i.e. the analogue perturbs the product RNA structure enough to stop further synthesis by the polymerase. Sofosbuvir is a pro-drug of 2'F-2'C-ME-UMP that has a 3'-OH but acts as a chain-terminator nonetheless 4 . In combination with other drugs, Sofosbuvir is widely and successfully used to cure HCV infections, but no data are available regarding activity against coronaviruses. A second MoA exists without termination or slow-down of RNA synthesis, but rather through high level incorporation of NA-TPs throughout the nascent RNA. These NAs are unable to be recognized as 'regular' Watson-Crick nucleobases during subsequent rounds of RNA synthesis from the NAcontaining template. This results in an increase in mutations and ultimately leads to non-viable genomes, a process known as 'lethal mutagenesis' 5 . Ribavirin (Rbv) and Favipiravir 6 belong to this class of antivirals, and are active against a variety of viruses (eg., HCV, influenza virus, Ebola virus). In the case of SARS-CoV, Rbv shows some efficacy in infected cells 7 , Rbv-5'-monophosphate (Rbv-MP) is incorporated into RNA in vitro 8 , however the drug does not control coronavirus replication in patients 9, 10 . Likewise, the mutagenic effect of β-D-N4 hydroxycytidine (EIDD-1931) and its isopropyl ester prodrug EIDD-2801 against a number of viruses has been demonstrated including coronaviruses 11 As RdRp domain of nsp12 (Fig 1A) , and only one of them (S783A) is a non-conservative mutation. We subsequently performed a structure-based alignment using the available Cryo-EM structure of SARS-CoV nsp12 to evaluate the potential structural and functional impact of the SARS-CoV-2 amino acid changes (Fig. 1B) . The SARS-CoV RdRp domain adopts a classical right hand fold with "Fingers", "Thumb", and "Palm" subdomains 26 . At both the structural and sequence levels, the conserved, canonical A to G motifs can be readily identified, and none of the mutations map within these motifs. We conclude that the SARS-CoV-2 RdRp structure and function is unlikely to differ significantly from that of SARS-CoV, which allows the latter to be considered as a faithful surrogate for structure/function analysis. In the absence of an X-ray or Cryo-EM structure of a ternary complex of a CoV RdRp bound to RNA template-primer and incoming nucleotide triphosphate (NTP), we took advantage of the structural and phylogenetic relatedness to picornavirus RdRps, for which the structures of several ternary RdRp-RNA-NTP elongation complexes exist 26 . Using the SARS-CoV nsp12 cryo-EM structure (PDB 6NUR), we built a model by stacking nsp12 onto a set of related RdRps described by Peersen 27 and used the T7 RNA polymerase ternary complex 28 to position both RNA and the incoming NTP. RNA and ATP were subsequently modelled at the SARS-CoV nsp12 active site. Overall, the structure is similar to that of the poliovirus polymerase: Motifs A-G encircle and constitute the polymerase active site, with an open NTP entry tunnel leading to the catalytic center ( Fig. 2A) . In CoV nsp12, motifs A,B,C,D and F the most conserved, and this conservation extends to Picornaviridae and Flaviviridae families 29 : it is thus reasonable to extrapolate that the mechanism of action is similar to that of other viral RdRps, and in particular to Picornaviridae with which CoVs share the "small thumb" feature 27 . The ribose moiety of the NTP poised to be incorporated is properly positioned by a conserved serine located in motif B and probably by residues of motif F (Fig. 2B , light blue and purple, see below). The spectrum of NAs active against human pathogenic CoVs has been recently reviewed 30 . Five NAs; Remdesivir, β-D-N4 hydroxycytidine, Gemcitabine, 6-Azauridine, Mizoribine and Acyclovir-Fleximer, show moderate-to-potent activity against three human pathogenic CoVs (SARS-CoV, MERS-CoV, and HCoV-NL63). One striking feature of this activity spectrum is the structural peculiarity of analogues relative to their potency towards CoVs as well as other RNA viruses. Obviously, the activity spectrum can be linked to either a modified ribose, a modified base, of both. Remdesivir (GS-5734) is one of the few nucleotide analogues reported to be active against SARS-CoV (reviewed in 30 ). It carries a cyano group on the 1' position of the ribose (1'-CN) and a 4-aza-7,9dideazaadenosine nucleobase (pseudo-adenine) linked to the ribose by a C-C bond (Fig. 2C ). Figure 3A shows the natural substrate ATP poised to receive the catalytic nucleophile attack on its αphosphate. Modelling GS 441524-TP at the nsp12 active site shows that the 1'-CN group is freely accommodated in the close vicinity of motif B (Fig. 3B) , a motif that has been reported to act as a fidelity check-point during active site closure with a conserved serine (here S682, see below) 29 . In Neither of the resistance mutations directly impact the catalytic site nor substrate-binding pocket, but rather cause minor structural alterations which likely impact an NTP 'checking step' performed by the polymerase before catalysis (Fig. 3A and B) : Residue F480 is located in the hydrophobic core of the protein, at the interface between the fingers and palm subdomains (Fig. 3C) . The phenyl ring is orientated towards hydrophobic residues from the palm (V637, L638) and the fingers (I579, V693), and plays a structural role in tightening the two domains by a strong mesh of hydrophobic interactions. In contrast, residue V557 is located at the end of motif F on the second strand forming the side of the RNA template entry channel (Fig. 3A) . Based on the theoretical model derived from the poliovirus polymerase elongation complex (4K4S) 31 , it can be predicted that the valine side chain faces the template RNA and interacts with the base to be paired with the incoming NTP. F480 is completely buried while V557 is partially exposed to solvent with solvent accessibility of 4.2 and 35.2 % respectively. Nevertheless, the server of protein thermodynamic stability changes upon single-site mutations 32 and predicts for both mutations a slight increase in Free energy (ΔG) of the protein, corresponding to a structural relaxation. The conserved F480L mutation reduces the amount of interactions within the hydrophobic core, thereby retaining the overall conformation while lowering the structural rigidity. The resulting increase of free energy should allow a greater degree of freedom of the secondary structure elements which harbors those hydrophobic residues. In related viral RdRps, the serine of motif B is thought to be responsible for allowing the proper positioning of the ribose moiety of the incoming NTP via the establishment of a hydrogen bond network with the 2' OH group of the ribose (Fig. 3A) . The structure of motif B is considered loose, but its conformational change upon binding the NTP is considered as a fidelity check point of viral RdRps 33 . Therefore, one possible interpretation is that phenylalanine to leucine mutation allows a relaxation in the positioning of the serine, leading to an altered fidelity check. Only detailed experimental work using, eg., pre-steady state kinetics, would determine how a better incorporation of ATP relative to that of GS 441524-TP might be achieved. Valine 557 is also located in the vicinity of motif B (Fig 3A and C) . The consequence of a valine to leucine mutation is an extended hydrophobic side chain, generating a steric hindrance with the template RNA. As a result, it is expected that the RNA would be deviated from the grove away from the serine of motif B. Again, it is possible to hypothesize that this deviation would alter the serine fidelity check, allowing easier incorporation of ATP relative to GS 441524-TP thus resulting in discrimination against the latter. Again, validation of this hypothesis requires detailed kinetics investigating nucleotide incorporation at the nsp12 active site. It is interesting to note that the nucleotide at the 3'-end shows some possible room at its 1'-position, hinting that GS 441524-TP, once incorporated, could potentially translocate (Fig. 3D) The overall identity of nsp14 sequences from the SARS-CoV Frankfurt isolate and the SARS-CoV-2 Wuhan-1 isolate is 95% regarding both the entire nsp14 gene and the ExoN domain alone (Fig. 4A) . Out of the 14 amino-acid changes in the ExoN domain, four involve non-conserved amino-acids. The ExoN active site has been structurally defined with three conserved motifs, DXE, W(X) 4 EL, and DAIMTR 37 . None of the amino-acid changes map to these motifs, which is confirmed by a structure based alignment performed in a similar way as that of Fig. 1 . Amino-acid changes can thus be considered as polymorphisms, and the SARS-CoV nsp14 ExoN domain can be considered a valid model for that of SARS-CoV-2. We took advantage of the SARS-CoV nsp14 crystal structure and the exonuclease structure of Lassa N protein 24 . Both proteins belong to the same DE(D/E)Dh family, and the Lassa N exoN domain has been crystallized with dsRNA, which thus allows modelling of the dsRNA into the nsp14 ExoN active site (Fig. 5 ). pseudo-adenine with surrounding nucleotides (Fig. 5C) . In other words, if the pseudo-adenine basepairs properly, the α-phosphate would be pushed away and unaligned for catalysis with the metal ions. It is thus likely that excision of GS 441524-MP is significantly less efficient than that of a regular nucleotide. Alternately, the GS 441524-MP might remain stuck in the polymerase active site as described above for delayed chain termination, and be inaccessible for excision. Taken together, the structural features of GS 441524-TP are consistent with the latter acting as a NA-TP substrate at the nsp12 active site, and a somehow disabled substrate for excision by the nsp14 ExoN, which could account for its anti-CoV effect. As proven by the recent SARS-CoV-2 outbreak, the emergence of new, significant human pathogens from zoonotic CoVs is a threat, and the development of broad-spectrum antivirals remains a priority. The RdRp domain remains an extremely attractive target for antivirals due to the high level of structural-conservation across diverse RNA viruses; denoting the potential for broad-spectrum applicability coupled with the advantage of having a relatively high barrier for resistance mutations. NAs constitute an attractive option, with success against several diverse RNA viruses. Nevertheless, CoVs are a particularly challenging case due to the additional presence of a unique exonuclease activity in their nsp14 gene product, which confers resistance to several commonly used NAs Interestingly, MHV V553 had been previously identified as a potential fidelity-regulating residue in CoVs based on comparison with known fidelity-altering mutants in the coxsackie B3 polymerase 23 . A V553I mutation engineered into murine hepatitis virus CoV was associated with a decrease in accumulation of mutations over time (a.k.a increased fidelity) and was shown to confer resistance to the mutagens 5-fluorouridine (5-FU) and 5-azacytidine (5-AZC). The conservation of fidelityregulating residues between distantly related RNA viruses indicates that these RdRps function in an analogous manner due to a high level of structural-conservation, despite limited sequence-similarity. To discover and design novel potent NAs against CoVs, an additional level of complexity has to be addressed relative to other RNA pathogenic viruses. NAs incorporated into coronaviral RNA have to escape the proofreading ExoN brought by the nsp14 N-terminus domain. In the absence nsp14 structural data at reasonable resolution for the drug-designer (ie., <2.5 Å) 8, 39 , and in complex with relevant substrates, we show here that the related Lassa virus N protein ExoN domain for which this type of data exist 24 can guide NA MoA studies. As shown in Figure 5 highlighting the A-G motifs. All structural models were made using Chimera 44 . Nidovirales: evolving the largest RNA virus genome Coronavirus as a possible cause of severe acute respiratory syndrome Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen In vitro and in vivo activities of anti-influenza virus compound T-705 In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area Oral Ribavirin for the Treatment of Noninfluenza Respiratory Viral Infections: A Systematic Review Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance Unique and conserved features of genome and proteome of SARScoronavirus, an early split-off from the coronavirus group 2 lineage Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults Lassa fever. Effective therapy with ribavirin Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Homology-Based Identification of a Mutation in the Coronavirus RNA-Dependent RNA Polymerase That Confers Resistance to Multiple Mutagens Structures of arenaviral nucleoproteins with triphosphate dsRNA reveal a unique mechanism of immune suppression Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors A Comprehensive Superposition of Viral Polymerase Structures The structural mechanism of translocation and helicase activity in T7 RNA polymerase Structurefunction relationships underlying the replication fidelity of viral RNA-dependent RNA polymerases Nucleoside analogues for the treatment of coronavirus infections Structures of Coxsackievirus, Rhinovirus, and Poliovirus Polymerase Elongation Complexes Solved by Engineering RNA Mediated Crystal Contacts Fast and accurate predictions of protein stability changes upon mutations using statistical potentials and neural networks: PoPMuSiC-2.0 Picornaviral polymerase structure, function, and fidelity modulation Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex Activity inhibition and crystal polymorphism induced by active-site metal swapping SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building ESPript/ENDscript: Extracting and rendering sequence and 3D information from atomic structures of proteins WebLogo: a sequence logo generator UCSF Chimera--a visualization system for exploratory research and analysis The authors would like to thank Veronique Fattorini for excellent technical assistance at various stages of this project. This work was performed with the support of REACTing, a multi-disciplinary collaborative network of French research institutions working on emerging infectious diseases, which aims to prepare and respond to epidemics, and the Fondation pour la Recherche Médicale (Aide aux équipes).